Synonym(s)
MK-0518; RGV
DefinitionThis section has been translated automatically.
Antiretrovirally active substance for the treatment of HIV infection. Inhibitor of the HIV integrase (strand transfer inhibitor).
Dosage and method of useThis section has been translated automatically.
2 times/day 400 mg p.o. applied. Boosting with ritonavir is not necessary.
You might also be interested in
Undesirable effectsThis section has been translated automatically.
Rarely nausea, dizziness, headaches, diarrhoea and fever. Due to the study situation no long-term data are available.
PreparationsThis section has been translated automatically.
Isentress
LiteratureThis section has been translated automatically.
- Jones J et al (2007) Advances in antiretroviral therapy. Top HIV Med 15: 48-82
- Kassahun K et al (2007) Metabolism and disposition in humans of raltegravir (MK-0518), on anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzymes. Drug Metab Dispos 35: 1657-1663
- Lataillade M, Kozal MJ (2006) The hunt for HIV-1 integrase inhibitors. AIDS Patient Care STDS 20: 489-501
- Lataillade M, Chiarella J, Kozal MJ (2007) Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance. Antivir Ther 12: 563-570
- Markowitz M et al (2007) Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr 46: 125-133
- Petitjean G et al (2007) Unintegrated HIV-1 provides an inducible and functional reservoir in untreated and highly active antiretroviral therapy-treated patients. Retrovirology 4: 60
- Stellbrink HJ (2007) Antiviral Drugs in the Treatment of AIDS: What is in the Pipeline? Eur J Med Res 12: 483-495
Prof. Dr. med. Peter Altmeyer